Table4_Cellular Senescence-Related Genes: Predicting Prognosis in Gastric Cancer.XLS

Our study aimed to explore the effect of cellular senescence and to find potential therapeutic strategies for gastric cancer. Cellular senescence-related genes were acquired from the CellAge database, while gastric cancer data were obtained from GEO and TCGA databases. SMARCA4 had the highest mutation frequency (6%), and it was linked to higher overall survival (OS) and progression-free survival (PFS). The gastric cancer data in TCGA database served as a training set to construct a prognostic risk score signature, and GEO data were used as a testing set to validate the accuracy of the signature. Patients with the low-risk score group had a longer survival time, while the high-risk score group is the opposite. Patients with low-risk scores had higher immune infiltration and active immune-related pathways. The results of drug sensitivity analysis and the TIDE algorithm showed that the low-risk score group was more susceptible to chemotherapy and immunotherapy. Most patients with mutation genes had a lower risk score than the wild type. Therefore, the risk score signature with cellular senescence-related genes can predict gastric cancer prognosis and identify gastric cancer patients who are sensitive to chemotherapy and immunotherapy.

本研究旨在探究细胞衰老（cellular senescence）的生物学作用，并探寻胃癌的潜在治疗策略。细胞衰老相关基因从CellAge数据库获取，胃癌数据来源于GEO与TCGA数据库。SMARCA4的突变频率最高（6%），且该基因与更优的总生存期（overall survival, OS）及无进展生存期（progression-free survival, PFS）相关。以TCGA数据库中的胃癌数据作为训练集构建预后风险评分特征，以GEO数据集作为测试集验证该特征的预测准确性。低风险评分组患者的生存时间更长，高风险评分组患者则呈现相反的结果。低风险评分组患者的免疫浸润水平更高，免疫相关通路更为活跃。药物敏感性分析与TIDE算法的结果显示，低风险评分组患者对化疗与免疫治疗更为敏感。多数携带突变基因的患者的风险评分低于野生型患者。综上，基于细胞衰老相关基因构建的预后风险评分特征可预测胃癌患者预后，并可筛选出对化疗及免疫治疗敏感的胃癌患者。